171 Results for Fraud Focus
  • Dive into the evolution of GLP-1 use

    New clinical publication from Prime Therapeutics explores the latest insights for GLP-1s, including trends in spend, drugs in the pipeline, management strategies and more

    Prime Article: Stories
  • GLP-1 Strategy

    Year 2 Prime Therapeutics’ leading research shows 1 in 12 remain on a GLP-1 drug for obesity at three years. Findings also show improved persistence with high-potency, obesity-approved GLP-1...

  • Expert clinical network

    Tap into our Expert Clinical Network Prime received a request for a nonformulary biologic in a young patient with severe Crohn’s disease, as the provider documented past failures of a biologic on...

  • Medicare and Managed Medicaid

    Footnotes When we say we are different from our competition, we truly mean it. At Prime, we are driven by our purpose of providing the care we would want for our loved ones. Explore how we stay...